SANTA CRUZ BIOTECHNOLOGY, INC.

plasminogen (GMA-016): sc-65964

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

Cleavage of the serine proteinase plasminogen to form plasmin is the central event in the dissolution of blood clots by the fibrinolytic system. Within the fibrinolytic cascade, the serine proteinases urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) activate the pro-enzyme plasminogen by cleaving plasminogen to form the fibrinolytically active enzyme plasmin. The enzyme plasmin consists of a heavy chain of 561 amino acids, which originates from the N-terminus of plasminogen, and a light chain of 230 amino acid residues, which is derived from the C-terminus of plasminogen. Plasmin is a proangiogenic proteinase that is capable of degrading a variety of extracellular matrix proteins and that facilitates endothelial cell migration and angiogenesis. In the presence of free sulfhydryl donors (FSD), plasmin undergoes auto-proteolysis and is converted to the enzyme angiostatin, which blocks angiogenesis and neovascularization and can inhibit the growth of primary and metastatic tumors.

REFERENCES

1. Forsgren, M., Raden, B., Israelsson, M., Larsson, K. and Heden, L.O. 1987. Molecular cloning and characterization of a full length cDNA clone for human plasminogen. FEBS Lett. 213: 254-260.
2. Petersen, T.E., Martzen, M.R., Ichinose, A. and Davie, E.W. 1990. Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J. Biol. Chem. 265: 6104-6111.
3. Christensen, L., Wiborg Simonsen, A.C., Heegaard, C.W., Moestrup, S.K., Andersen, J. and Andreasen, P.A. 1996. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α_2-Macroglobulin receptor in human breast carcinomas. Int. J. Cancer. 66: 441-452.
4. Gately, S., Twardowski, P., Stack, M.S., Cundiff, D.L., Grella, D., Castellino, F.J., Enghild, J., Kwaan, H.C., Lee, F., Kramer, R.A., Volpert, O., Bouck, N. and Soff, G.A. 1997. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA 94: 10868-10872.
5. Falcone, D.J., Khan, K.M., Layne, T. and Fernandes, L. 1998. Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen. J. Biol. Chem. 273: 31480-31485.
6. Morikawa, W., Yamamoto, K., Ishikawa, S., Takemoto, S., Ono, M., Fukushi, J., Naito, S., Nozaki, C., Iwanaga, S. and Kuwano, M. 2000. Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J. Biol. Chem. 275: 38912-38920.
7. Andreasen, P.A., Egelund, R. and Petersen, H.H. 2000. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57: 25-40.

CHROMOSOMAL LOCATION

Genetic locus: PLG (human) mapping to 6q26.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

SOURCE

plasminogen (GMA-016) is a mouse monoclonal antibody raised against plasminogen of human origin, with epitope mapping to the kringles 1-4 segment of plasminogen.

PRODUCT

Each vial contains 100 µg IgG_1 in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

plasminogen (GMA-016) is recommended for detection of plasminogen and angiostatin of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000).

Suitable for use as control antibody for plasminogen siRNA (h): sc-40857, plasminogen shRNA Plasmid (h): sc-40857-SH and plasminogen shRNA (h) Lentiviral Particles: sc-40857-V.

Molecular Weight of plasminogen: 90-100 kDa.

Positive Controls: human kidney tumor tissue.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.